KR100784161B1 - 항종양제로서 c7 에스테르 치환된 탁산 - Google Patents

항종양제로서 c7 에스테르 치환된 탁산 Download PDF

Info

Publication number
KR100784161B1
KR100784161B1 KR1020017012600A KR20017012600A KR100784161B1 KR 100784161 B1 KR100784161 B1 KR 100784161B1 KR 1020017012600 A KR1020017012600 A KR 1020017012600A KR 20017012600 A KR20017012600 A KR 20017012600A KR 100784161 B1 KR100784161 B1 KR 100784161B1
Authority
KR
South Korea
Prior art keywords
pyridyl
furyl
thienyl
taxane
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017012600A
Other languages
English (en)
Korean (ko)
Other versions
KR20010111583A (ko
Inventor
로버트 에이. 홀튼
Original Assignee
플로리다 스테이트 유니버시티 리서치 파운데이션, 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크 filed Critical 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크
Publication of KR20010111583A publication Critical patent/KR20010111583A/ko
Application granted granted Critical
Publication of KR100784161B1 publication Critical patent/KR100784161B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020017012600A 2000-02-02 2001-02-02 항종양제로서 c7 에스테르 치환된 탁산 Expired - Fee Related KR100784161B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17979400P 2000-02-02 2000-02-02
US60/179,794 2000-02-02

Publications (2)

Publication Number Publication Date
KR20010111583A KR20010111583A (ko) 2001-12-19
KR100784161B1 true KR100784161B1 (ko) 2007-12-12

Family

ID=22658029

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017012600A Expired - Fee Related KR100784161B1 (ko) 2000-02-02 2001-02-02 항종양제로서 c7 에스테르 치환된 탁산

Country Status (35)

Country Link
US (3) US6610860B2 (enExample)
EP (1) EP1183253B8 (enExample)
JP (1) JP2003522167A (enExample)
KR (1) KR100784161B1 (enExample)
CN (1) CN1362955A (enExample)
AR (1) AR030188A1 (enExample)
AT (1) ATE396188T1 (enExample)
AU (1) AU776051B2 (enExample)
BG (1) BG65279B1 (enExample)
BR (1) BR0104749A (enExample)
CA (1) CA2368993C (enExample)
CO (1) CO5280224A1 (enExample)
CZ (1) CZ298484B6 (enExample)
DE (1) DE60134094D1 (enExample)
DK (1) DK1183253T3 (enExample)
ES (1) ES2307588T3 (enExample)
GE (1) GEP20043322B (enExample)
HK (1) HK1047938A1 (enExample)
HU (1) HUP0200917A3 (enExample)
IL (1) IL145641A0 (enExample)
MX (1) MXPA01009901A (enExample)
MY (1) MY137637A (enExample)
NO (1) NO327982B1 (enExample)
NZ (1) NZ514409A (enExample)
PL (1) PL202668B1 (enExample)
PT (1) PT1183253E (enExample)
RO (1) RO121777B1 (enExample)
RU (1) RU2265017C2 (enExample)
SA (1) SA01220045B1 (enExample)
SK (1) SK13712001A3 (enExample)
TR (1) TR200102856T1 (enExample)
TW (1) TWI291873B (enExample)
UA (1) UA75573C2 (enExample)
WO (1) WO2001057027A1 (enExample)
ZA (1) ZA200108060B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
US6638973B2 (en) * 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
CA2354486A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C7 ester substituted taxanes
SG125889A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C7 ester subsituted taxanes
KR100819578B1 (ko) * 2001-08-01 2008-04-04 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크 C7 에스테르 치환된 탁산
US20030082229A1 (en) * 2001-11-01 2003-05-01 Board Of Regents, The University Of Texas Systems Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
US8012950B2 (en) * 2003-08-29 2011-09-06 Wisconsin Alumni Research Foundation Method to diagnose and treat degenerative joint disease
JP4874102B2 (ja) 2003-09-25 2012-02-15 タペストリー ファーマシューティカルズ インコーポレーテッド 9,10−α,α−OH−タキサンアナログおよびその生成のための方法
EP1810968A3 (en) * 2003-09-25 2007-08-08 Tapestry Pharmaceuticals, Inc. 9, 10-a, a-OH-taxane analogs and methods for production thereof
JP2007527432A (ja) * 2004-03-05 2007-09-27 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド C7ラクチルオキシ置換タキサン
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
EP1812864A2 (en) * 2004-10-07 2007-08-01 Emory University Multifunctional nanoparticles conjugates and their use
KR101292026B1 (ko) 2004-10-25 2013-08-01 데크-테크 인코포레이티드 종양 치료제로서의 이소포스포르아미드 머스타드 및 이의동족체의 염
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
EP1913958B1 (en) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008098138A1 (en) 2007-02-07 2008-08-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic macrocyclic compounds for treating cancer
WO2008109360A1 (en) 2007-02-28 2008-09-12 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
KR101505415B1 (ko) 2007-04-06 2015-03-25 지오팜 온콜로지 인코포레이티드 이소포스포르아미드 머스타드의 염 및 이의 동족체
NZ603801A (en) 2008-07-31 2014-01-31 Ziopharm Oncology Inc Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
JP5779106B2 (ja) 2009-02-24 2015-09-16 デック−テック, インコーポレイテッド 抗腫瘍剤としての4−ヒドロペルオキシイホスファミドの錯体
WO2010138686A1 (en) 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
US9492405B2 (en) 2010-03-10 2016-11-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2012033601A1 (en) 2010-08-20 2012-03-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Thiosemicarbazones with mdr1 - inverse activity
JP6127045B2 (ja) 2011-07-11 2017-05-10 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 光増感抗体−蛍光団コンジュゲート
EP2854855B1 (en) 2012-05-25 2016-04-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
ES2960807T3 (es) 2013-10-11 2024-03-06 Us Health Anticuerpos contra TEM8 y su uso
CN111388672A (zh) 2014-08-08 2020-07-10 美国政府(由卫生和人类服务部的部长所代表) 在体内和在体外的靶标的光控移除
CN111556757A (zh) 2017-10-31 2020-08-18 西方溶瘤细胞有限公司 用于全身递送的平台溶瘤载体
WO2019099615A1 (en) 2017-11-17 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth
JP2021521135A (ja) 2018-04-10 2021-08-26 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ がん細胞を標的とする近赤外光線免疫療法および宿主免疫活性化の組合せ
EP3994173A1 (en) 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
WO2021154705A1 (en) 2020-01-27 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
EP4247410A4 (en) 2020-11-19 2025-05-07 KaliVir Immunotherapeutics, Inc. ONCOLYTIC IMMUNOTHERAPY BY TUMOR MICROENVIRONMENT REMOVAL
AU2022213415A1 (en) 2021-01-29 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
WO2024006965A1 (en) 2022-06-30 2024-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd25-specific antibodies and uses thereof
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013495A1 (en) * 1994-10-28 1996-05-09 The Research Foundation Of State University Of New York Taxoid derivatives, their preparation and their use as antitumor agents

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
SE463189B (sv) 1989-03-13 1990-10-22 Eston Joensson Preparat avsett att tillfoeras amalgamfyllningar i taender foer att daerigenom hindra eller minska avgaang av kvicksilver eller kvicksilveraanga
US5175315A (en) 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
FR2679230B1 (fr) 1991-07-16 1993-11-19 Rhone Poulenc Rorer Sa Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent.
US5243045A (en) 1991-09-23 1993-09-07 Florida State University Certain alkoxy substituted taxanes and pharmaceutical compositions containing them
US5227400A (en) 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5489601A (en) * 1991-09-23 1996-02-06 Florida State University Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5714513A (en) 1991-09-23 1998-02-03 Florida State University C10 taxane derivatives and pharmaceutical compositions
SG46582A1 (en) 1991-09-23 1998-02-20 Univ Florida State 10-Desacetoxytaxol derivatives
US5721268A (en) 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5430160A (en) 1991-09-23 1995-07-04 Florida State University Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
RU2059631C1 (ru) * 1991-11-29 1996-05-10 Дзе Юниверсити оф Канзас Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью
ATE280240T1 (de) 1992-01-15 2004-11-15 Squibb & Sons Inc Enzymatische verfahren zur aüftrennüng von enantiomeren-mischungen nützlich als zwischenprodukte zur herstellung von taxanen
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
DE69325454T2 (de) 1992-04-17 2000-01-20 Abbott Laboratories, Abbott Park Taxol-derivate
US5248796A (en) 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5319112A (en) 1992-08-18 1994-06-07 Virgnia Tech Intellectual Properties, Inc. Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
HU222175B1 (hu) 1992-12-23 2003-04-28 Bristol-Myers Squibb Co. Oldalláncot hordozó taxánszármazékok és eljárások előállításukra
IL108443A0 (en) * 1993-01-29 1994-04-12 Univ Florida State C7 taxane derivatives and pharmaceutical compositions containing them
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
CA2158863C (en) * 1993-03-22 2006-12-19 Robert A. Holton Taxanes having a pyridyl substituted side-chain
PT1228759E (pt) * 1993-03-22 2005-04-29 Univ Florida State Composicoes farmaceuticas contendo um taxano possuindo uma cadeia lateral substituida com furilo ou tienilo
EP0690711B1 (en) * 1993-03-22 2000-08-16 Florida State University Taxanes having an amino substituted side-chain
DK0703909T3 (da) 1993-06-11 2000-09-11 Upjohn Co Delta6,7-taxoler, antineoplastisk anvendelse og farmaceutiske præparater indeholdende dem
IL109926A (en) 1993-06-15 2000-02-29 Bristol Myers Squibb Co Methods for the preparation of taxanes and microorganisms and enzymes utilized therein
TW397866B (en) 1993-07-14 2000-07-11 Bristol Myers Squibb Co Enzymatic processes for the resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes
FR2711369B1 (fr) 1993-10-20 1995-11-17 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions qui les contiennent.
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5414869A (en) * 1993-11-26 1995-05-16 Thomson; Margaret I. Knotless scarf and method of making same
FR2721024B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
TW354293B (en) 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5780653A (en) 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
CA2231837A1 (en) 1995-09-13 1997-03-20 Florida State University Radiosensitizing taxanes and their pharmaceutical preparations
US5767297A (en) 1997-02-05 1998-06-16 Ensuiko Sugar Refining Co., Ltd. Taxoid derivative and method of producing thereof
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0927175A4 (en) 1996-05-06 2002-05-22 Univ Florida State 1-DEOXYBACCATIN III, 1-DEOXYTAXOL AND 1-DEOXYTAXOL ANALOG AND METHOD FOR THE PRODUCTION THEREOF
AU3122597A (en) * 1996-05-17 1997-12-09 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CA2255615C (en) * 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
US5811452A (en) 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
WO1999018113A1 (fr) * 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
US6136988A (en) 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same
US5964739A (en) * 1998-06-18 1999-10-12 Champ; Raynido A. Safety disposable needle structure
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
CA2375343A1 (en) 1999-06-21 2000-12-28 Napro Biotherapeutics, Inc. C-2 hydroxyl protected-n-acyl(2r,3s)-3-phenylisoserine activated esters and methods for production thereof
US6348215B1 (en) 1999-10-06 2002-02-19 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
CO5280224A1 (es) * 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
IL145635A0 (en) 2000-02-02 2002-06-30 Univ Florida State Res Found Taxane formulations having improved solubility
US6638973B2 (en) * 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
IT1319168B1 (it) 2000-03-17 2003-09-26 Indena Spa Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013495A1 (en) * 1994-10-28 1996-05-09 The Research Foundation Of State University Of New York Taxoid derivatives, their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
MY137637A (en) 2009-02-27
AR030188A1 (es) 2003-08-13
EP1183253B8 (en) 2009-01-07
NO327982B1 (no) 2009-11-02
NZ514409A (en) 2004-03-26
EP1183253B1 (en) 2008-05-21
WO2001057027A1 (en) 2001-08-09
CA2368993C (en) 2009-10-20
KR20010111583A (ko) 2001-12-19
UA75573C2 (en) 2006-05-15
ZA200108060B (en) 2003-12-01
JP2003522167A (ja) 2003-07-22
NO20014759D0 (no) 2001-10-01
DE60134094D1 (de) 2008-07-03
MXPA01009901A (es) 2003-07-28
CA2368993A1 (en) 2001-08-09
HUP0200917A3 (en) 2004-07-28
ES2307588T3 (es) 2008-12-01
BG65279B1 (bg) 2007-11-30
HK1047938A1 (zh) 2003-03-14
US20070249708A1 (en) 2007-10-25
AU3323901A (en) 2001-08-14
EP1183253A1 (en) 2002-03-06
AU776051B2 (en) 2004-08-26
BR0104749A (pt) 2001-12-26
SK13712001A3 (sk) 2002-05-09
TWI291873B (en) 2008-01-01
BG105967A (en) 2002-08-30
US7186849B2 (en) 2007-03-06
ATE396188T1 (de) 2008-06-15
CZ20013503A3 (cs) 2002-03-13
NO20014759L (no) 2001-11-29
PL350026A1 (en) 2002-10-21
DK1183253T3 (da) 2008-09-22
HUP0200917A2 (en) 2002-08-28
HU0200917D0 (en) 2002-04-29
US20040014979A1 (en) 2004-01-22
CO5280224A1 (es) 2003-05-30
US6610860B2 (en) 2003-08-26
PL202668B1 (pl) 2009-07-31
PT1183253E (pt) 2008-08-04
RO121777B1 (ro) 2008-04-30
TR200102856T1 (tr) 2002-06-21
SA01220045B1 (ar) 2008-06-07
CN1362955A (zh) 2002-08-07
GEP20043322B (en) 2003-12-10
CZ298484B6 (cs) 2007-10-17
IL145641A0 (en) 2002-06-30
US20020013346A1 (en) 2002-01-31
RU2265017C2 (ru) 2005-11-27

Similar Documents

Publication Publication Date Title
KR100784161B1 (ko) 항종양제로서 c7 에스테르 치환된 탁산
KR100791361B1 (ko) 항종양제로서 c10 에스테르 치환된 탁산
KR20020002488A (ko) 항종양제로서 c10 헤테로치환된 아세테이트 탁산
KR20010111580A (ko) 개선된 용해도를 갖는 탁산 제형물
KR20010111582A (ko) 항종양제로서 c10 카르보네이트 치환된 탁산
EP1200424B1 (en) C7 heterosubstituted acetate taxanes as antitumor agents
US6780879B2 (en) C7 carbonate substituted taxanes
KR20020000159A (ko) 항종양제로서의 c10 카르바모일옥시 치환된 탁산
KR20020002417A (ko) 항종양제로서의 c7 카르바모일옥시 치환된 탁산
WO2001057032A1 (en) C10 ester substituted taxanes as antitumor agents
KR100819578B1 (ko) C7 에스테르 치환된 탁산
KR100815455B1 (ko) C10 에스테르 치환된 탁산

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20101205

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20101205

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000